Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dose-escalation Study to Assess the Safety and Tolerability of Sub-cutaneous Injections of a Peptide-loaded Plasmacytoid Dendritic Cell Line (GeniusVac-Mel4) in Patients With Melanoma

NCT01863108 is registered in ClinicalTrials.gov with University Hospital, Grenoble as lead sponsor.

NCT NCT01863108
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01863108 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dose-escalation Study to Assess the Safety and Tolerability of Sub-cutaneous Injections of a Peptide-loaded Plasmacytoid Dendritic Cell Line (GeniusVac-Mel4) in Patients With Melanoma
Lead sponsor
University Hospital, Grenoble
Phase
Phase 1
Overall status
Completed
Start date
June 30, 2013
Completion date
March 23, 2017
Enrollment
9 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

effects of immunotherapy, melanoma, tumor vaccines